Analyst Price Targets — LAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 4, 2024 2:41 am | Matthew Stanton | Jefferies | $3.25 | $2.66 | StreetInsider | Jefferies Starts Standard BioTools Inc (LAB) at Buy, 'Platform Building & Setting a New Standard' |
Latest News for LAB
BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025.
Standard BioTools (NASDAQ: LAB - Get Free Report) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect Standard BioTools to post earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page
BOSTON, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after U.S. market close.
Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments
Standard BioTools (NASDAQ: LAB - Get Free Report) and Clover Health Investments (NASDAQ: CLOV - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations. Profitability This table compares Standard BioTools
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LAB.
U.S. House Trading
No House trades found for LAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.